BNP Paribas Financial Markets’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1
| Closed | -$5 | – | 4307 |
|
|
2021
Q3 | $5 | Hold |
1
| – | – | ﹤0.01% | 4003 |
|
|
2021
Q2 | $5 | Hold |
1
| – | – | ﹤0.01% | 4042 |
|
|
2021
Q1 | $5 | Hold |
1
| – | – | ﹤0.01% | 3980 |
|
|
2020
Q4 | $4 | Hold |
1
| – | – | ﹤0.01% | 4134 |
|
|
2020
Q3 | $4 | Sell |
1
-19,488
| -100% | -$75.4K | ﹤0.01% | 4195 |
|
|
2020
Q2 | $49.9K | Buy |
19,489
+12,307
| +171% | +$36.2K | ﹤0.01% | 3029 |
|
|
2020
Q1 | $20.8K | Buy |
7,182
+1,534
| +27% | +$6.88K | ﹤0.01% | 3902 |
|
|
2019
Q4 | $21.4K | Buy |
5,648
+2,037
| +56% | +$9.75K | ﹤0.01% | 3983 |
|
|
2019
Q3 | $18.5K | Buy |
3,611
+1,100
| +44% | +$6.79K | ﹤0.01% | 3979 |
|
|
2019
Q2 | $15.6K | Sell |
2,511
-2,146
| -46% | -$12.3K | ﹤0.01% | 3983 |
|
|
2019
Q1 | $33.1K | Buy |
+4,657
| New | +$41.9K | ﹤0.01% | 3723 |
|
|
2018
Q4 | – | Sell |
-713
| Closed | -$14.3K | – | 4480 |
|
|
2018
Q3 | $14.3K | Hold |
713
| – | – | ﹤0.01% | 3581 |
|
|
2018
Q2 | $18.4K | Sell |
713
-2,916
| -80% | -$80.7K | ﹤0.01% | 3531 |
|
|
2018
Q1 | $86.7K | Buy |
3,629
+452
| +14% | +$14.3K | ﹤0.01% | 3262 |
|
|
2017
Q4 | $108K | Buy |
3,177
+1,504
| +90% | +$42K | ﹤0.01% | 3265 |
|
|
2017
Q3 | $35.4K | Sell |
1,673
-114
| -6% | -$2.09K | ﹤0.01% | 3321 |
|
|
2017
Q2 | $31.3K | Buy |
1,787
+1,756
| +5,665% | +$29K | ﹤0.01% | 3425 |
|
|
2017
Q1 | $543 | Sell |
31
-249
| -89% | -$4.24K | ﹤0.01% | 3834 |
|
|
2016
Q4 | $4.73K | Sell |
280
-893
| -76% | -$13.8K | ﹤0.01% | 3731 |
|
|
2016
Q3 | $19.2K | Buy |
1,173
+520
| +80% | +$7.9K | ﹤0.01% | 2915 |
|
|
2016
Q2 | $9.89K | Buy |
+653
| New | +$10.8K | ﹤0.01% | 2921 |
|
|
2016
Q1 | – | Sell |
-2,046
| Closed | -$57.9K | – | 3234 |
|
|
2015
Q4 | $57.9K | Sell |
2,046
-15
| -0.7% | -$253 | ﹤0.01% | 2709 |
|
|
2015
Q3 | $34.5K | Buy |
2,061
+1,196
| +138% | +$27.2K | ﹤0.01% | 3099 |
|
|
2015
Q2 | $22.7K | Buy |
865
+795
| +1,136% | +$15.5K | ﹤0.01% | 2964 |
|
|
2015
Q1 | $1.22K | Buy |
+70
| New | +$1.2K | ﹤0.01% | 3538 |
|
|
2014
Q4 | – | Sell |
-92
| Closed | -$1.71K | – | 3473 |
|
|
2014
Q3 | $1.71K | Buy |
+92
| New | +$1.58K | ﹤0.01% | 3958 |
|
BNP Paribas Financial Markets's ADMS Position: Q4 2021 in Review
BNP Paribas Financial Markets sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1 share — an estimated $5 sold.
BNP Paribas Financial Markets first reported a position in ADMS in Q3 2014 and held it in 26 quarters. The position peaked at $108K in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- BNP Paribas Financial Markets reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 1 Adamas Pharmaceuticals share in Q4 2021, an estimated $5.
- BNP Paribas Financial Markets first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 26 quarters.
- BNP Paribas Financial Markets's Adamas Pharmaceuticals position peaked at $108K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2021, filed 9 Feb 2022.